(Boursier.com) — The laboratory Ipsen confirmed the finalization of the definitive merger agreement for the acquisition of the American company Epizyme. Under the terms of the transaction, Ipsen is acquiring all of the outstanding shares of Epizyme at a price of $1.45 per share plus a Guaranteed Value Certificate (CVG) of $1 per share. Epizyme now operates as “an Ipsen Group company” following the closing of the acquisition.
As part of the transaction, Ipsen acquires Epizyme’s lead drug, Tazverik (tazemetostat), a first-in-class, non-chemotherapy EZH2 inhibitor, which has received US regulatory approval (FDA) ‘fast track in 2020. It is currently indicated in adults with relapsed or refractory follicular lymphoma (FL) whose tumor is positive for an EZH2 mutation, detected by an FDA-approved test, and who received at least two previous systemic treatments, in adults with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment, as well as in adults and children aged 16 and over with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
Ipsen also acquires Epizyme’s oral SETD2 inhibitor drug candidate under development, EZM0414, first in its class, which obtained a fast track designation from the FDA in 2021. EZM0414 is in the process of being evaluation in a recently initiated Phase I/Ib trial in adult patients with relapsed or refractory multiple myeloma or diffuse large B-cell lymphoma, as well as a portfolio of preclinical programs focused on epigenetic targets.